VSL # 3 and remission in active ulcerative colitis: Larger studies required

American Journal of Gastroenterology

Volumn 106, Issue 3, 2011, Pages 547-

  Jackson, Emma L ^a   Hamlin, P John ^a   Ford, Alexander C ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; METHOTREXATE; VSL3;

DIET RESTRICTION; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LETTER; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; BIFIDOBACTERIUM; COLITIS, ULCERATIVE; DIET; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LACTOBACILLUS; MESALAMINE; METHOTREXATE; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 79952342457     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.451     Document Type: Letter

References (2)

1. Tursi A, Brandimarte G, Papa A et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL # 3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105:2218-27.
2. Sood A, Midha V, Makharia GK et al. The probiotic preparation, VSL # 3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1202-9.